anemia
Very preliminary analysis of an ongoing phase III trial studying two erythropoietin doses given continuously subcutaneously versus a retrospective analysis of a "control group" (drawn from historical data on the occurrence of anemia in cisplatin- and/or carboplatin-treated patients) has shown beneficial effects of erythropoietin during treatment with these platinating agents.
Very preliminary analysis of an ongoing phase III trial studying two <span class="gene" id="8202718-5-69-83">erythropoietin</span> doses given continuously subcutaneously versus a retrospective analysis of a "control group" (drawn from historical data on the occurrence of <span class="disease" id="8202718-5-226-232">anemia</span> in cisplatin- and/or carboplatin-treated patients) has shown beneficial effects of <span class="gene" id="8202718-5-316-330">erythropoietin</span> during treatment with these platinating agents.